Posted on 8月 1, 20238/1/23
Commercial Key Success Factors (KSFs) for Global Drug Development Programs
Posted on 4月 17, 20234/17/23
What EVERSANA’s Growing Abstract Count at ISPOR U.S. Means to the HEOR Industry
Posted on 10月 12, 202210/12/22
The Evolution of HTA and Its Impact on Drug Prices in Japan
Posted on 4月 14, 20224/14/22
Impact of Patient Reported Outcome Measures on HTA Decisions for Rare Diseases
Posted on 4月 1, 20224/1/22
What You Need to Know as the European Union Embarks on Joint Health Technology Assessment (HTA)
Posted on 12月 21, 202112/21/21
Launch Sequencing and Market Prioritization in an Evolving Global Market
Posted on 12月 6, 202112/6/21
Considering Commercial Success During Clinical Development: Maintaining a Global Perspective
Posted on 11月 9, 202111/9/21
EPP Keynote Address: Global Pricing and Market Access Hurdles for Innovation
Posted on 10月 26, 202110/26/21
Health Technology Assessment in the Asia Pacific Region
Posted on 12月 4, 202012/4/20